BioSpace News Archive

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), today announced that they have completed a successful Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) regarding the Accelerated Approval pathway for pegunigalsidase alfa (PRX‑102) for the treatment of Fabry disease.

Study data presented at AHA show Eko DUO combined with advanced artificial intelligence algorithm effectively identifies low ejection fraction in patients

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic research collaboration to discover and develop novel targeted conditioning regimens that may enhance the hematopoietic stem cell transplant process, including transplants conducted as part of treatment with ex vivo CRISPR/Cas9 gene editing therapies such as CTX001.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxxwill participate in a fireside chat and host one-on-one meetings with investors at the 31st Annual Piper Jaffray Healthcare Conference on December 3rd, 2019 at the Lotte New York Palace in New York, NY.

UAVenture Capital Fund, a Tucson-based venture capital fund dedicated to the commercialization of University of Arizona discoveries, products, technologies and services, announced its thirteenth investment.

Merck Canada Inc., an affiliate of Merck & Co., Inc., known as MSD outside the United States and Canada, announced today that reimbursement will be provided to PIFELTRO® and DELSTRIGO®, a once-daily NNRTI regimen for the treatment of HIV-1 infection, effective October 31st for the Ontario Drug Benefit Program and November 14th for la Régie de l’assurance maladie du Québec, RAMQ.

Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, announced today it has reached an agreement to acquire Zürich, Switzerland-based Biovotion AG, a leading developer of a cutting-edge clinical-grade wearable biosensor platform

Lavie Bio (Lavie), a subsidiary of Evogene (NASDAQ: EVGN) (TASE: EVGN), aiming to improve food quality, sustainability and agriculture productivity through the introduction of microbiome based ag-biological products, announces today phase advancement in its product development pipeline for wheat bio-stimulants

KIYATEC, Inc. and CarThera announce today that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma, a highly aggressive form of brain cancer that afflicts more than 130,000 patients worldwide per year and is characterized by historically poor clinical outcomes.

AgilVax Inc., a biopharmaceutical company that discovers and develops targeted antibody-based therapeutics, announced today that preclinical data describing M5, the Company’s monoclonal antibody targeting xCT, will be presented by Dr. Salameh at the American Association for Cancer Research’s Tumor Immunology and Immunotherapy Conference being held at the Boston Marriott Copley Place in Boston, MA.